Biocon’s Mylan resubmits MAAs for Biosimilar Trastuzumab and Pegfilgrastim Dossiers

07 Nov 2017 Evaluate

Biocon’s partner Mylan has resubmitted the Marketing Authorization Applications (MAAs) for its proposed biosimilar trastuzumab and pegfilgrastim with the European Medicines Agency (EMA) as per the administrative protocol. This follows the earlier withdrawal of both applications in response to the audit of our aseptic drug product facility by the designated European authority.

Biocon has completed the Corrective and Preventive Actions (CAPAs), including the facility modifications, in response to the audit observations and expects these to be verified during re-inspection.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

384.05 -8.75 (-2.23%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×